비교리스트

 카트 문의
시장보고서
상품코드
1385469

아시아태평양의 다중 암 검사 시장 - 분석 및 예측(2023-2032년)

Asia-Pacific Multicancer Screening Market - Analysis and Forecast, 2023-2032
발행일: | 리서치사: BIS Research | 페이지 정보: 영문 | 배송안내 : 1-5일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

2022년 현재 아시아태평양의 다중 암 검사 시장 규모는 2억 7,000만 달러로 평가되며, 2032년에는 14억 달러에 달할 것으로 예상됩니다.

암 발병률의 증가와 액체 생검 검사의 사용 확대는 아시아태평양의 다중 암 검사 시장의 성장을 촉진할 것으로 예상됩니다.

주요 시장 통계
예측 기간 2023-2032년
2023년 평가 3억 2,000만 달러
2032년 예측 14억 달러
CAGR 17.6%

아시아태평양(APAC) 지역의 다중 암 검사 시장은 의료 인프라를 개선하고 다양한 악성 종양의 발병률 증가에 대응하기 위해 노력함에 따라 크게 성장할 것으로 예상됩니다. 첨단 진단 기술을 통해 여러 암종을 동시에 검출하는 다중 암 검사는 조기 발견이 치료 결과를 개선하는 데 중요한 역할을 한다는 인식이 높아지면서 아시아태평양에서 점점 더 널리 보급되고 있습니다. 이 시장은 암 예방 및 통제 이니셔티브의 증가, 고령화 및 검진 기술의 기술적 도약에 힘입어 성장세를 보이고 있습니다. 아시아태평양 정부와 의료 기관이 종합적인 암 검진 프로그램 도입에 중점을 두면서 다중 암 검사 시장이 성장하고 있으며, 보다 접근성이 높고 정확한 암 진단에 대한 수요가 증가함에 따라 아시아태평양 다중 암 검사 시장도 성장할 것으로 예상됩니다.

이 보고서는 아시아태평양의 다중 암 검사 시장에 대해 조사했으며, 시장 개요와 함께 국가별 동향, 시장 진입 기업 개요 등을 제공합니다.

목차

제1장 시장

  • 제품 정의
  • 포함 기준과 제외 기준
  • 시장 범위
  • 조사 방법

제2장 시장 개요

  • 시장 개요
  • 다중 암 검사 워크플로우 분석
  • 시장 발자국과 성장 가능성
  • 잠재성
  • COVID-19에 의한 시장에 대한 영향

제3장 업계 인사이트

  • 특허 분석
  • 상환 시나리오
  • 공급망 분석
  • 가격 분석(테스트 유형별)

제4장 시장 역학

  • 개요
  • 영향 분석
  • 시장 촉진요인
  • 시장 과제
  • 시장 기회

제5장 경쟁 상황

  • 주요 전략과 전개
  • 시장 점유율 분석(2022년)
  • 성장 점유율 분석(2022년)

제6장 아시아태평양

  • 개요
  • 아시아태평양

제7장 시장 - 기업 개요

  • 개요
  • 다중 암 검사 시장 시장 밸류체인
  • 다중 암 검사 생태계 진출 기업
  • Burning Rock DX
  • Genecast Biotechnology Co., Ltd
  • Konica Minolta, Inc.(Ambry Genetics.)
ksm 23.12.01

“The Asia-Pacific Multicancer Screening Market Expected to Reach $1.40 Billion by 2032.”

Introduction to Asia-Pacific (APAC) Multicancer Screening Market

As of 2022, the Asia-Pacific multicancer screening market was valued at $0.27 billion and is expected to attain a value of $1.40 billion by 2032. The rising incidence of cancer and growing use of liquid biopsy testing are anticipated to fuel market expansion for multicancer screening in Asia-Pacific.

KEY MARKET STATISTICS
Forecast Period2023 - 2032
2023 Evaluation$0.32 Billion
2032 Forecast$1.40 Billion
CAGR17.6%

Market Introduction

The market for multicancer screening in Asia-Pacific (APAC) is expected to develop significantly as the area concentrates on improving healthcare infrastructure and tackling the increased incidence of different malignancies. The practice of multicancer screening, which is the simultaneous detection of numerous cancer types by sophisticated diagnostic techniques, is becoming more and more popular throughout Asia-Pacific as people become more aware of the critical role that early detection plays in enhancing treatment outcomes. The market is being pushed by increasing initiatives for cancer prevention and control, an aging population, and technical breakthroughs in screening technologies. The multicancer screening market is growing as a result of governments and healthcare organizations in the Asia-Pacific area placing a strong emphasis on the adoption of comprehensive cancer screening programs. The market for APAC multicancer screening is expected to grow as demand increases for more accessible and precise cancer diagnosis.

Market Segmentation

Segmentation 1: by Country

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest-of-Asia-Pacific

In 2021, China was the leading contributor to the Asia-Pacific multicancer screening market, with a market share of 32.64%. Japan is the second-largest contributor to the Asia-Pacific multicancer screening market.

How can this report add value to an organization?

Product/Innovation Strategy: The report considers multicancer screening kit/panel and assay product-based companies. The industry is seeing constant development and product launches with new and innovative upgrades. Additionally, new discoveries of specific biomarkers related to various cancer types are increasing researchers' trust in multicancer sequencing.

Growth/Marketing Strategy: The key components in multicancer screening are the kits and the related technologies for sample analysis. The advancements in new analysis methods like liquid biopsy are influencing the growth of this market. Additionally, the discovery of biomarkers and other genes for various diseases is helping panel manufacturers curate precise kits and assays for multicancer screening of various cancer types.

Competitive Strategy: The key players in the Asia-Pacific multicancer screening market have been analyzed and profiled in the study, consisting of most product-based companies, as well as a few emerging companies. Moreover, a detailed competitive benchmarking of the players operating in the Asia-Pacific multicancer screening market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts, analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

  • Burning Rock DX
  • Genecast Biotechnology Co., Ltd.
  • Konica Minolta, Inc. (Ambry Genetics.)

Table of Contents

1 Markets

  • 1.1 Product Definition
  • 1.2 Inclusion and Exclusion Criteria
  • 1.3 Market Scope
    • 1.3.1 Scope of the Study
    • 1.3.2 Key Questions Answered in the Report
  • 1.4 Research Methodology
    • 1.4.1 Asia-Pacific Multicancer Screening Market: Research Methodology
    • 1.4.2 Data Sources
    • 1.4.3 Market Estimation Model
    • 1.4.4 Criteria for Company Profiling

2 Market Overview

  • 2.1 Market Overview
  • 2.2 Multicancer Screening Workflow Analysis
  • 2.3 Market Footprint and Growth Potential
  • 2.4 Future Potential
  • 2.5 COVID-19 Impact on the Market

3 Industry Insights

  • 3.1 Patent Analysis
    • 3.1.1 Patent Filing Trend
    • 3.1.2 Patent Analysis (by Country)
    • 3.1.3 Patent Analysis (by Region)
  • 3.2 Reimbursement Scenario
  • 3.3 Supply Chain Analysis
  • 3.4 Pricing Analysis (by Test Type)

4 Market Dynamics

  • 4.1 Overview
  • 4.2 Impact Analysis
  • 4.3 Market Drivers
    • 4.3.1 Early Detection of Cancer Leads to Higher Survival Chances and Better Treatment
    • 4.3.2 Increasing Popularity of Liquid Biopsy Leading to Easier Screening
    • 4.3.3 Reduced Treatment Cost Due to Earlier Cancer Detection
  • 4.4 Market Challenges
    • 4.4.1 Lack of Awareness about the Multicancer Screening Tests
    • 4.4.2 Too Costly to be Used as Preventive Care
  • 4.5 Market Opportunities
    • 4.5.1 Robust Pipeline of Multicancer Screening Tests Poised to Revolutionize Cancer Diagnosis
    • 4.5.2 New Biomarkers being Discovered Regularly

5 Competitive Landscape

  • 5.1 Key Strategies and Developments
    • 5.1.1 Mergers and Acquisitions
    • 5.1.2 Synergistic Activities
    • 5.1.3 Product Launches and Upgradations
    • 5.1.4 Funding and Expansion
  • 5.2 Market Share Analysis (2022)
  • 5.3 Growth-Share Analysis (2022)
    • 5.3.1 Growth-Share Analysis (by Technology)

6 Asia-Pacific

  • 6.1 Overview
  • 6.2 Asia-Pacific
    • 6.2.1 China
    • 6.2.2 Japan
    • 6.2.3 India
    • 6.2.4 Australia
    • 6.2.5 South Korea
    • 6.2.6 Rest-of-Asia-Pacific

7 Markets - Company Profiles

  • 7.1 Overview
  • 7.2 Market Value Chain of Multicancer Screening Market
  • 7.3 Multicancer Screening Ecosystem Active Players
  • 7.4 Burning Rock DX
    • 7.4.1 Company Overview
    • 7.4.2 Role of Burning Rock DX in the Asia-Pacific Multicancer Screening Market
    • 7.4.3 Key Competitors of the Company
    • 7.4.4 Business Strategies
    • 7.4.5 Analyst Perspective
  • 7.5 Genecast Biotechnology Co., Ltd
    • 7.5.1 Company Overview
    • 7.5.2 Role of Genecast Biotechnology Co., Ltd in the Asia-Pacific Multicancer Screening Market
    • 7.5.3 Key Competitors of the Company
    • 7.5.4 Analyst Perspective
  • 7.6 Konica Minolta, Inc. (Ambry Genetics.)
    • 7.6.1 Company Overview
    • 7.6.2 Role of Konica Minolta, Inc. (Ambry Genetics.) in the Asia-Pacific Multicancer Screening Market
    • 7.6.3 Key Competitors of the Company
    • 7.6.4 Financials
    • 7.6.5 Analyst Perspective
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제